The Sinovac vaccine has a lower efficacy rate than its domestic Chinese competitor, developed by the state-owned Sinopharm, which it says has a 79.34% efficacy.

Sinovac said its COVID-19 vaccine is safe in children ages 3-17, based on preliminary data, and it has submitted the data to Chinese drug regulators.

A Sinovac Biotech Ltd. minority investor fighting for a $600 million dividend and board changes at the vaccine company is ...

Sinovac began work on a Covid-19 vaccine soon after a top Chinese epidemiologist disclosed on national television in late January that the coronavirus in Wuhan was being transmitted between humans.

Chinese SinoVac Biotech Ltd. (Nasdaq: SVA) shares have been frozen since 2019 amid shareholder disputes when market cap was ...

Without seeing the full data from all the Sinovac vaccine trials, it's impossible to know for sure, Dean notes. But even if the Sinovac vaccine is only around 50% protective, that's still substantial.

Washington, D.C. – The U.S. Defense Department admitted it spread propaganda in the Philippines aimed at disparaging China’s Sinovac vaccine during the COVID-19 pandemic, according to a June ...

SinoVac’s COVID-19 vaccine, dubbed CoronaVac, has begun phase 3 trials involving 9,000 volunteers in Brazil. ‘We will share our vaccine with the world,’ says SinoVac CEO Yin Weidong ...

Previously, three other vaccines by SINOVAC were also approved by WHO in various uses and conditions, including Healive® (the hepatitis A vaccine), CoronaVac® (the COVID-19 vaccine) and the ...

The Sinovac vaccine has a lower efficacy rate than its domestic Chinese competitor, developed by the state-owned Sinopharm, which it says has a 79.34% efficacy.